Area of research
Rheumatology · Psychiatry and Mental health
Research interest
Research interests include Rheumatoid Arthritis Research and Therapies, Spondyloarthritis Studies and Treatments, Fibromyalgia and Chronic Fatigue Syndrome Research, and Systemic Lupus Erythematosus Research.
Interpretable inflammation landscape of circulating immune cells
Understanding the immunopathophysiology of polymyalgia rheumatica: implications for treatment.
Changes in bone mineral density and fractures during 2 years of low-dose glucocorticoid treatment for rheumatoid arthritis: a systematic literature review and individual participant data meta-analysis.
Decision on Optimal Combinatorial Therapies in Immune-mediated inflammatory diseases using Systems approaches (DocTIS): protocol for a single-arm, adaptive basket trial in rheumatoid and psoriatic arthritis.
Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trial.
Thank you to the reviewers of
<i>Rheumatology</i>
2025
Efficacy, safety, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab intravenously administered to adults with active rheumatoid arthritis and an inadequate response to methotrexate: a phase 3, randomised study
Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes.
Enhancing current guidance for psoriatic arthritis and its comorbidities: recommendations from an expert consensus panel.
How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients.
Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: Rasch measurement theory to identify items and domains.
The use of combination advanced therapies in psoriatic arthritis: results from a UK multi-centre audit.
Mapping for Better Care: Supporting service planning for people with rheumatic and musculoskeletal conditions
Mapping for Better Care: Supporting service planning for people with rheumatic and musculoskeletal conditions
Assessing the content validity of a Patient Reported Outcome Measure item pool for Rheumatoid Arthritis Disease Activity using cognitive interviews.
The pattern of anti-IL-6 versus non-anti-IL-6 biologic disease modifying anti-rheumatic drugs use in patients with rheumatoid arthritis in Wales, UK: a real-world study using electronic health records.
Validity and contributions to pain from the central aspects of pain questionnaire in rheumatoid arthritis.
Patterns of Healthcare Use, Comorbidities, and Treatment of Fibromyalgia: Insights from Survey and Administrative Healthcare Data in Scotland and Wales
P112 Cytokine driven disease and epigenetic heterogeneity in rheumatoid arthritis
Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases.
Defining domains: developing consensus-based definitions for foundational domains in OMERACT core outcome sets.
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years.
An international multicentre analysis of current prescribing practices and shared decision-making in psoriatic arthritis.
The pattern of anti-IL-6 versus non-anti-IL-6 biologic disease modifying anti-rheumatic drugs use in patients with rheumatoid arthritis in Wales, UK: a real-world study using electronic health records
Correction: Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry.
Introduction to the new Editor-in-Chief
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis